Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Donauwörth

7 clinical trials in Donauwörth, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Donauwörth at a glance
7
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

7 trials in Donauwörth

Open in trial search
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:University Of Cologne
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Eli Lilly & Co.
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Universitaetsklinikum Ulm AöR
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Eli Lilly & Co.
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Hydroxycarbamide
  • Sponsor:Novartis Pharma GmbH

Other cities in Germany

The busiest research cities in the country

All 515 cities in Germany

Clinical research in Donauwörth

What the registry says about research in the country

01 Breast Cancer Research

Advanced clinical trials focusing on hormone receptor-positive HER2-negative breast cancer treatments, evaluating innovative therapeutic combinations.

  • Endocrine therapy optimization
  • Novel drug combinations
  • Treatment resistance studies

Investigating breakthrough therapies including imlunestrant and abemaciclib for improving patient outcomes.

02 Hematologic Oncology

Groundbreaking research in chronic lymphocytic leukemia, specifically targeting high-risk patients with genetic mutations.

  • Triple combination therapy evaluation
  • High-risk CLL management
  • Targeted treatment approaches

Testing innovative combinations of acalabrutinib, obinutuzumab, and venetoclax.

03 Blood Disorders

Innovative studies in polycythemia vera treatment, incorporating artificial intelligence for predicting therapy outcomes.

  • Treatment resistance prediction
  • AI-assisted patient care
  • Hydroxyurea effectiveness

Evaluating treatment resistance patterns using machine learning algorithms through the PV-AIM project.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.